These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 31812535)
1. Heparanase promotes myeloma stemness and in vivo tumorigenesis. Tripathi K; Ramani VC; Bandari SK; Amin R; Brown EE; Ritchie JP; Stewart MD; Sanderson RD Matrix Biol; 2020 Jun; 88():53-68. PubMed ID: 31812535 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912 [TBL] [Abstract][Full Text] [Related]
3. Heparanase: From basic research to therapeutic applications in cancer and inflammation. Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844 [TBL] [Abstract][Full Text] [Related]
4. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190 [TBL] [Abstract][Full Text] [Related]
5. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152 [TBL] [Abstract][Full Text] [Related]
15. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells. Alberti L; Losi L; Leyvraz S; Benhattar J PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996 [TBL] [Abstract][Full Text] [Related]
16. Heparanase enhances myeloma progression via CXCL10 downregulation. Barash U; Zohar Y; Wildbaum G; Beider K; Nagler A; Karin N; Ilan N; Vlodavsky I Leukemia; 2014 Nov; 28(11):2178-87. PubMed ID: 24699306 [TBL] [Abstract][Full Text] [Related]
17. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. Purushothaman A; Chen L; Yang Y; Sanderson RD J Biol Chem; 2008 Nov; 283(47):32628-36. PubMed ID: 18812315 [TBL] [Abstract][Full Text] [Related]
18. Heparanase: A Dynamic Promoter of Myeloma Progression. Purushothaman A; Sanderson RD Adv Exp Med Biol; 2020; 1221():331-349. PubMed ID: 32274716 [TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles released during hypoxia transport heparanase and enhance macrophage migration, endothelial tube formation and cancer cell stemness. Tripathi K; Bandari SK; Sanderson RD Proteoglycan Res; 2023 Jan; 1(1):. PubMed ID: 37091070 [TBL] [Abstract][Full Text] [Related]
20. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline. Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]